摘要
分析了罗氟司特片结合沙美特罗替卡松吸入气雾剂治疗慢性阻塞性肺疾病(COPD)的效果及安全性。将56例COPD患者随机分成两组,对照组以沙美特罗替卡松吸入气雾剂治疗,观察组加用罗氟司特片,比较两组患者的疗效和治疗安全性。结果显示观察组患者肺功能指标、临床疗效、6min步行距离均优于对照组(P<0.05);观察组患者1年内急性发作次数、发作间隔时间、住院总时间均明显少于对照组(P<0.05)。两组患者的不良反应差异不显著(P>0.05)。研究发现,对COPD患者以罗氟司特片结合沙美特罗替卡松吸入气雾剂治疗,能有效改善患者肺功能,提升其运动耐量,疗效显著,且用药方案比较安全,值得推广。
The efficacy and safety of roflukast combined with salmeterol and fluticasone inhalation aerosol in the treatment of COPD were analyzed.56 patients with COPD were randomly divided into two groups.The control group was treated with salmeterol and fluticasone inhalation aerosol,while the observation group was treated with roflukast tablets.The efficacy and safety of the two groups were compared.The results showed that the lung function index,clinical efficacy,and 6-minute walking distance of the patients in the observation group were better than those in the control group(P<0.05);The number of acute episodes,interval between episodes,and total hospital stay in the observation group were significantly lower than those in the control group within one year(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Research has found that the treatment of COPD patients with roflukast tablets combined with salmeterol and fluticasone inhaled aerosol can effectively improve lung function and exercise tolerance,with significant efficacy,and the drug regimen is relatively safe,which is worth promoting.
作者
冯志根
FENG Zhigen(Mengcun Town Central Health Center of Xingbin District,Laibin,Guangxi 546124)
出处
《科技与健康》
2022年第8期57-59,共3页
Technology and Health
